UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2018
OR
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number 001-36794
The Chemours Company
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
46-4845564 |
(State or other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
1007 Market Street, Wilmington, Delaware 19899
(Address of Principal Executive Offices)
(302) 773-1000
(Registrant’s Telephone Number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ☒ |
Accelerated Filer ☐ |
Non-Accelerated Filer ☐ |
Smaller reporting company ☐ |
|
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The registrant had 177,911,882 shares of common stock, $0.01 par value, outstanding at April 30, 2018.
TABLE OF CONTENTS
|
|
Page |
Part I |
|
|
Item 1. |
|
|
|
2 |
|
|
Interim Consolidated Statements of Comprehensive Income (Unaudited) |
3 |
|
4 |
|
|
Interim Consolidated Statements of Stockholders’ Equity (Unaudited) |
5 |
|
6 |
|
|
Notes to the Interim Consolidated Financial Statements (Unaudited) |
7 |
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
38 |
Item 3. |
57 |
|
Item 4. |
57 |
|
|
|
|
Part II |
|
|
Item 1. |
58 |
|
Item 1A. |
59 |
|
Item 2. |
59 |
|
Item 3. |
60 |
|
Item 4. |
60 |
|
Item 5. |
60 |
|
Item 6. |
60 |
|
|
|
61 |
|
|
62 |
1
Item 1. |
INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
The Chemours Company
Interim Consolidated Statements of Operations (Unaudited)
(Dollars in millions, except per share amounts)
|
|
Three Months Ended March 31, |
|
|||||
|
|
2018 |
|
|
2017 |
|
||
Net sales |
|
$ |
1,730 |
|
|
$ |
1,437 |
|
Cost of goods sold |
|
|
1,193 |
|
|
|
1,081 |
|
Gross profit |
|
|
537 |
|
|
|
356 |
|
Selling, general, and administrative expense |
|
|
143 |
|
|
|
150 |
|
Research and development expense |
|
|
20 |
|
|
|
19 |
|
Restructuring, asset-related, and other charges, net |
|
|
10 |
|
|
|
12 |
|
Total expenses |
|
|
173 |
|
|
|
181 |
|
Equity in earnings of affiliates |
|
|
12 |
|
|
|
7 |
|
Interest expense, net |
|
|
(52 |
) |
|
|
(51 |
) |
Other income, net |
|
|
57 |
|
|
|
42 |
|
Income before income taxes |
|
|
381 |
|
|
|
173 |
|
Provision for income taxes |
|
|
84 |
|
|
|
22 |
|
Net income |
|
|
297 |
|
|
|
151 |
|
Less: Net income attributable to non-controlling interests |
|
|
— |
|
|
|
1 |
|
Net income attributable to Chemours |
|
$ |
297 |
|
|
$ |
150 |
|
|
|
|
|
|
|
|
|
|
Per share data |
|
|
|
|
|
|
|
|
Basic earnings per share of common stock |
|
$ |
1.63 |
|
|
$ |
0.82 |
|
Diluted earnings per share of common stock |
|
|
1.58 |
|
|
|
0.79 |
|
Dividends per share of common stock |
|
|
— |
|
|
|
0.03 |
|
See accompanying notes to the interim consolidated financial statements.
2
Interim Consolidated Statements of Comprehensive Income (Unaudited)
(Dollars in millions)
|
|
Three Months Ended March 31, |
|
|||||||||||||||||||||
|
|
2018 |
|
|
2017 |
|
||||||||||||||||||
|
|
Pre-tax |
|
|
Tax |
|
|
After-tax |
|
|
Pre-tax |
|
|
Tax |
|
|
After-tax |
|
||||||
Net income |
|
$ |
381 |
|
|
$ |
(84 |
) |
|
$ |
297 |
|
|
$ |
173 |
|
|
$ |
(22 |
) |
|
$ |
151 |
|
Other comprehensive (loss) income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized loss on net investment hedge |
|
|
(34 |
) |
|
|
8 |
|
|
|
(26 |
) |
|
|
(10 |
) |
|
|
— |
|
|
|
(10 |
) |
Cumulative translation adjustment |
|
|
108 |
|
|
|
— |
|
|
|
108 |
|
|
|
103 |
|
|
|
— |
|
|
|
103 |
|
Defined benefit plans: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additions to accumulated other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of foreign exchange rates |
|
|
(9 |
) |
|
|
— |
|
|
|
(9 |
) |
|
|
(10 |
) |
|
|
2 |
|
|
|
(8 |
) |
Reclassifications to net income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of actuarial loss |
|
|
4 |
|
|
|
(1 |
) |
|
|
3 |
|
|
|
5 |
|
|
|
(1 |
) |
|
|
4 |
|
Defined benefit plans, net |
|
|
(5 |
) |
|
|
(1 |
) |
|
|
(6 |
) |
|
|
(5 |
) |
|
|
1 |
|
|
|
(4 |
) |
Other comprehensive income |
|
|
69 |
|
|
|
7 |
|
|
|
76 |
|
|
|
88 |
|
|
|
1 |
|
|
|
89 |
|
Comprehensive income |
|
|
450 |
|
|
|
(77 |
) |
|
|
373 |
|
|
|
261 |
|
|
|
(21 |
) |
|
|
240 |
|
Less: Comprehensive income attributable to non-controlling interests |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
|
— |
|
|
|
1 |
|
Comprehensive income attributable to Chemours |
|
$ |
450 |
|
|
$ |
(77 |
) |
|
$ |
373 |
|
|
$ |
260 |
|
|
$ |
(21 |
) |
|
$ |
239 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to the interim consolidated financial statements.
3
Interim Consolidated Balance Sheets
(Dollars in millions, except per share amounts)
|
|
(Unaudited) |
|
|
|
|
|
|
|
|
March 31, 2018 |
|
|
December 31, 2017 |
|
||
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
1,434 |
|
|
$ |
1,556 |
|
Accounts and notes receivable, net |
|
|
1,083 |
|
|
|
919 |
|
Inventories |
|
|
992 |
|
|
|
935 |
|
Prepaid expenses and other |
|
|
75 |
|
|
|
83 |
|
Total current assets |
|
|
3,584 |
|
|
|
3,493 |
|
Property, plant, and equipment |
|
|
8,719 |
|
|
|
8,511 |
|
Less: Accumulated depreciation |
|
|
(5,614 |
) |
|
|
(5,503 |
) |
Property, plant, and equipment, net |
|
|
3,105 |
|
|
|
3,008 |
|
Goodwill and other intangible assets, net |
|
|
165 |
|
|
|
166 |
|
Investments in affiliates |
|
|
166 |
|
|
|
173 |
|
Other assets |
|
|
464 |
|
|
|
453 |
|
Total assets |
|
$ |
7,484 |
|
|
$ |
7,293 |
|
Liabilities |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,121 |
|
|
$ |
1,075 |
|
Current maturities of long-term debt |
|
|
14 |
|
|
|
15 |
|
Other accrued liabilities |
|
|
487 |
|
|
|
558 |
|
Total current liabilities |
|
|
1,622 |
|
|
|
1,648 |
|
Long-term debt, net |
|
|
4,141 |
|
|
|
4,097 |
|
Deferred income taxes |
|
|
244 |
|
|
|
208 |
|
Other liabilities |
|
|
475 |
|
|
|
475 |
|
Total liabilities |
|
|
6,482 |
|
|
|
6,428 |
|
Commitments and contingent liabilities |
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 185,903,112 shares issued and 178,537,554 shares outstanding at March 31, 2018; 185,343,034 shares issued and 182,956,628 shares outstanding at December 31, 2017) |
|
|
2 |
|
|
|
2 |
|
Treasury stock at cost (7,365,558 shares at March 31, 2018; 2,386,406 shares at December 31, 2017) |
|
|
(361 |
) |
|
|
(116 |
) |
Additional paid-in capital |
|
|
846 |
|
|
|
837 |
|
Retained earnings |
|
|
876 |
|
|
|
579 |
|
Accumulated other comprehensive loss |
|
|
(366 |
) |
|
|
(442 |
) |
Total Chemours stockholders’ equity |
|
|
997 |
|
|
|
860 |
|
Non-controlling interests |
|
|
5 |
|
|
|
5 |
|
Total equity |
|
|
1,002 |
|
|
|
865 |
|
Total liabilities and equity |
|
$ |
7,484 |
|
|
$ |
7,293 |
|
See accompanying notes to the interim consolidated financial statements.
4
Interim Consolidated Statements of Stockholders’ Equity (Unaudited)
(Dollars in millions)
|
|
Common Stock |
|
|
Treasury Stock |
|
|
Additional Paid-In |
|
|
(Accumulated Deficit) Retained |
|
|
Accumulated Other Comprehensive |
|
|
Non-controlling |
|
|
|
|
|
||||||||||||||
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Earnings |
|
|
(Loss) Income |
|
|
Interests |
|
|
Total Equity |
|
|||||||||
Balance at January 1, 2017 |
|
|
182,600,533 |
|
|
$ |
2 |
|
|
|
— |
|
|
$ |
— |
|
|
$ |
789 |
|
|
$ |
(114 |
) |
|
$ |
(577 |
) |
|
$ |
4 |
|
|
$ |
104 |
|
Common stock issued - compensation plans |
|
|
415,518 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Exercise of stock options, net |
|
|
1,382,363 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
20 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
20 |
|
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6 |
|
Cancellation of unissued stock awards withheld to cover taxes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(7 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(7 |
) |
Net income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
150 |
|
|
|
— |
|
|
|
1 |
|
|
|
151 |
|
Dividends paid |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(5 |
) |
|
|
— |
|
|
|
— |
|
|
|
(5 |
) |
Other comprehensive income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
89 |
|
|
|
— |
|
|
|
89 |
|
Balance at March 31, 2017 |
|
|
184,398,414 |
|
|
$ |
2 |
|
|
|
— |
|
|
$ |
— |
|
|
$ |
808 |
|
|
$ |
31 |
|
|
$ |
(488 |
) |
|
$ |
5 |
|
|
$ |
358 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2018 |
|
|
182,956,628 |
|
|
$ |
2 |
|
|
|
2,386,406 |
|
|
$ |
(116 |
) |
|
$ |
837 |
|
|
$ |
579 |
|
|
$ |
(442 |
) |
|
$ |
5 |
|
|
$ |
865 |
|
Common stock issued - compensation plans |
|
|
286,618 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Exercise of stock options, net |
|
|
273,460 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5 |
|
Purchases of treasury stock at cost |
|
|
(4,979,152 |
) |
|
|
— |
|
|
|
4,979,152 |
|
|
|
(245 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(245 |
) |
Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
9 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
9 |
|
Cancellation of unissued stock awards withheld to cover taxes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(5 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(5 |
) |
Net income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
297 |
|
|
|
— |
|
|
|
— |
|
|
|
297 |
|
Other comprehensive income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
76 |
|
|
|
— |
|
|
|
76 |
|
Balance at March 31, 2018 |
|
|
178,537,554 |
|
|
$ |
2 |
|
|
|
7,365,558 |
|
|
$ |
(361 |
) |
|
$ |
846 |
|
|
$ |
876 |
|
|
$ |
(366 |
) |
|
$ |
5 |
|
|
$ |
1,002 |
|
See accompanying notes to the interim consolidated financial statements.
5
Interim Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
|
|
Three Months Ended March 31, |
|
|||||
|
|
2018 |
|
|
2017 |
|
||
Cash flows from operating activities |
|
|
|
|
|
|
|
|
Net income |
|
$ |
297 |
|
|
$ |
151 |
|
Adjustments to reconcile net income to cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
70 |
|
|
|
71 |
|
Gain on sale of assets and businesses |
|
|
(42 |
) |
|
|
(16 |
) |
Equity in earnings of affiliates, net |
|
|
17 |
|
|
|
(7 |
) |
Amortization of deferred financing costs and issuance discount |
|
|
3 |
|
|
|
3 |
|
Deferred tax provision |
|
|
35 |
|
|
|
5 |
|
Other operating charges and credits, net |
|
|
8 |
|
|
|
10 |
|
Decrease (increase) in operating assets: |
|
|
|
|
|
|
|
|
Accounts and notes receivable, net |
|
|
(150 |
) |
|
|
(103 |
) |
Inventories and other operating assets |
|
|
(29 |
) |
|
|
(31 |
) |
(Decrease) increase in operating liabilities: |
|
|
|
|
|
|
|
|
Accounts payable and other operating liabilities |
|
|
(13 |
) |
|
|
(42 |
) |
Cash provided by operating activities |
|
|
196 |
|
|
|
41 |
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Purchases of property, plant, and equipment |
|
|
(102 |
) |
|
|
(69 |
) |
Proceeds from sales of assets and businesses, net |
|
|
39 |
|
|
|
9 |
|
Foreign exchange contract settlements, net |
|
|
5 |
|
|
|
(3 |
) |
Cash used for investing activities |
|
|
(58 |
) |
|
|
(63 |
) |
Cash flows from financing activities |
|
|
|
|
|
|
|
|
Debt repayments |
|
|
(4 |
) |
|
|
(4 |
) |
Purchases of treasury stock at cost |
|
|
(240 |
) |
|
|
— |
|
Proceeds from exercised stock options, net |
|
|
5 |
|
|
|
20 |
|
Tax payments related to withholdings on vested restricted stock units |
|
|
(1 |
) |
|
|
— |
|
Payment of dividends |
|
|
(31 |
) |
|
|
(5 |
) |
Cash (used for) provided by financing activities |
|
|
(271 |
) |
|
|
11 |
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
11 |
|
|
|
7 |
|
Decrease in cash and cash equivalents |
|
|
(122 |
) |
|
|
(4 |
) |
Cash and cash equivalents at January 1, |
|
|
1,556 |
|
|
|
902 |
|
Cash and cash equivalents at March 31, |
|
$ |
1,434 |
|
|
$ |
898 |
|
|
|
|
|
|
|
|
|
|
Supplemental cash flows information |
|
|
|
|
|
|
|
|
Non-cash investing and financing activities: |
|
|
|
|
|
|
|
|
Changes in property, plant, and equipment included in accounts payable |
|
$ |
(1 |
) |
|
$ |
14 |
|
Obligations incurred under build-to-suit lease arrangement |
|
|
11 |
|
|
|
— |
|
Purchases of treasury stock not settled by quarter-end |
|
|
15 |
|
|
|
— |
|
Tax payments accrued for withholdings on vested restricted stock units |
|
|
4 |
|
|
|
— |
|
See accompanying notes to the interim consolidated financial statements.
6
The Chemours Company
Notes to the Interim Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share amounts)
Note 1. Background, Description of the Business, and Basis of Presentation
The Chemours Company (Chemours, or the Company) is a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. The Company delivers customized solutions with a wide range of industrial and specialty chemical products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. The Company’s principal products include refrigerants, industrial fluoropolymer resins, sodium cyanide, performance chemicals and intermediates, and titanium dioxide (TiO2) pigment. Chemours’ business consists of three reportable segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. The Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrials, and consumer applications. The Titanium Technologies segment is a leading, global provider of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications.
The accompanying interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles (GAAP) in the United States of America (U.S.) for interim financial information. In the opinion of management, all adjustments (consisting of normal, recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. The Company’s results for interim periods should not be considered indicative of its results for a full year, and the year-end consolidated balance sheet does not include all of the disclosures required by GAAP. As such, these interim consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
Unless the context otherwise requires, references herein to “The Chemours Company,” “Chemours,” “the Company,” “our Company,” “we,” “us,” and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to “DuPont” refer to E. I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.
Note 2. Recent Accounting Pronouncements
Accounting Guidance Issued and Not Yet Adopted
Leases
In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) (ASU No. 2016-02), which supersedes the leases requirements in Topic 840. The core principle of ASU No. 2016-02 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months. Recognition of these lease assets and lease liabilities represents a change from previous GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases. Qualitative disclosures along with specific quantitative disclosures will be required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities.
The Company will be required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that the Company may elect to apply. The provisions of ASU No. 2016-02 are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. At adoption, the Company will recognize a right-of-use asset and a lease liability initially measured at the present value of its operating lease payments. The Company is currently evaluating the impacts of adopting this guidance on its financial position, results of operations, and cash flows.
7
The Chemours Company
Notes to the Interim Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share amounts)
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815) (ASU No. 2017-12), which simplifies financial statement reporting for qualifying hedging relationships by eliminating the requirement to separately measure and report hedge ineffectiveness. For net investment hedges, the entire change in fair value of the hedging instruments is recorded in the currency translation adjustment section of other comprehensive income or loss. Pursuant to the amendments, these amounts are required to be subsequently reclassified to earnings in the same income statement line item in which the earnings effect of the hedged item is presented when the hedged item affects earnings. The provisions of ASU No. 2017-12 are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year. Early adoption is permitted in any interim period. The amendments in this update will be applied to hedging relationships existing on the date of adoption, which includes a cumulative-effect adjustment to eliminate any ineffectiveness recorded to accumulated other comprehensive income or loss with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year in which adoption occurred. Presentation and disclosure amendments are required to be applied prospectively. Chemours is currently evaluating the timing of adoption and does not expect that the adoption of this guidance will have a significant impact on its financial position, results of operations, and cash flows.
Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income
In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (ASU No. 2018-02), which allows for a reclassification from accumulated other comprehensive income or loss to retained earnings for stranded tax effects resulting from U.S. tax reform. The amendments in this update also require certain disclosures about stranded tax effects. ASU No. 2018-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company does not expect that the adoption of this guidance will have a significant impact on its financial position.
Recently Adopted Accounting Guidance
Revenue from Contracts with Customers
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU No. 2014-09). The objective of this standard is to remove inconsistent practices with regard to revenue recognition between GAAP and International Financial Reporting Standards. The standard intends to improve the comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets. Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with the standard (collectively, Topic 606).
Effective January 1, 2018, Chemours adopted the new revenue recognition guidance contained in Topic 606 using the modified retrospective transition method. The Company elected to utilize a practical expedient allowed under the modified retrospective transition method to apply the new standard only to contracts that are not completed on the date of initial adoption. In applying this guidance, the Company evaluated its population of open contracts with customers on January 1, 2018 and determined that the impact of adopting Topic 606 was not material to its consolidated financial statements as a whole, and no cumulative adjustment to the Company’s opening retained earnings balance was required. As a result of applying this new guidance, there are changes to the classification of certain amounts in the consolidated statements of operations. Certain royalty income amounts for trademark licensing arrangements that were previously reflected as a component of other income, net in the consolidated statements of operations will now be reflected as a component of net sales, which amounted to $2 for the three months ended March 31, 2018. Additionally, certain expenses related to the Company’s provision of technical services to customers that were previously reflected as a component of selling, general, and administrative expense in the consolidated statements of operations will now be reflected as a component of the cost of goods sold, which amounted to $1 for the three months ended March 31, 2018. Under the modified retrospective transition method, the Company’s comparative financial information as of and for the three months ended March 31, 2017 and as of December 31, 2017 has not been restated, and as such, continues to be reported using the accounting standards in effect during those time periods.
8
The Chemours Company
Notes to the Interim Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share amounts)
The following table sets forth the impacts of the adoption of Topic 606 on the Company’s consolidated statements of operations for the three months ended March 31, 2018.
|
|
Three Months Ended March 31, 2018 |
|
|||||||||
|
|
Without |
|
|
Topic 606 |
|
|
|
|
|
||
|
|
Topic 606 |
|
|
Adjustments |
|
|
As Reported |
|
|||
Net sales |
|
$ |
1,728 |
|
|
$ |
2 |
|
|
$ |
1,730 |
|
Cost of goods sold |
|
|
1,192 |
|
|
|
1 |
|
|
|
1,193 |
|
Gross profit |
|
|
536 |
|
|
|
1 |
|
|
|
537 |
|
Selling, general, and administrative expense |
|
|
144 |
|
|
|
(1 |
) |
|
|
143 |
|
Research and development expense |
|
|
20 |
|
|
|
— |
|
|
|
20 |
|
Restructuring, asset-related, and other charges, net |
|
|
10 |
|
|
|
— |
|
|
|
10 |
|
Total expenses |
|
|
174 |
|
|
|
(1 |
) |
|
|
173 |
|
Equity in earnings of affiliates |
|
|
12 |
|
|
|
— |
|
|
|
12 |
|
Interest expense, net |
|
|
(52 |
) |
|
|
— |
|
|
|
(52 |
) |
Other income, net |
|
|
59 |
|
|
|
(2 |
) |
|
|
57 |
|
Income before income taxes |
|
|
381 |
|
|
|
— |
|
|
|
381 |
|
Provision for income taxes |
|
|
84 |
|
|
|
— |
|
|
|
84 |
|
Net income |
|
|
297 |
|
|
|
— |
|
|
|
297 |
|
Less: Net income attributable to non-controlling interests |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net income attributable to Chemours |
|
$ |
297 |
|
|
$ |
— |
|
|
$ |
297 |
|
The adoption of Topic 606 did not impact the Company’s consolidated balance sheets or consolidated statements of cash flows as of and for the three months ended March 31, 2018 and is not expected to have a material impact on the Company’s financial position, results of operations, or cash flows in future periods.
Classification of Certain Cash Receipts and Cash Payments
In August 2016, the FASB issued various updates to ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU No. 2016-15), which clarifies and amends the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The provisions of ASU No. 2016-15 are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and are to be applied using a retrospective transition method. The Company adopted ASU No. 2016-15 on January 1, 2018, the impact of which was not material to its cash flows. There were no adjustments to prior periods resulting from the retrospective application of this guidance.
Clarifying the Definition of a Business
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (ASU No. 2017-01), which changes the definition of a business to assist entities in evaluating whether a transaction should be accounted for as an acquisition (or disposal) of assets or a business. ASU No. 2017-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2018, the result of which is not expected to have a significant impact on its financial position, results of operations, or cash flows.
9
The Chemours Company
Notes to the Interim Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share amounts)
In March 2017, the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715) (ASU No. 2017-07), which requires that employers offering their employees defined benefit pension plans disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The provisions of ASU No. 2017-07 are effective for fiscal years beginning after December 31, 2017, as well as interim periods within those fiscal years, and should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic post-retirement benefit cost in the income statement, and prospectively for the capitalization of the service cost component of net periodic pension cost and net periodic post-retirement benefit in assets. The Company adopted this guidance on January 1, 2018, which resulted in a reclassification of non-operating pension income from the operating expense captions of the consolidated statements of operations to other income, net for the three months ended March 31, 2017.
The following table sets forth a reclassification of the Company’s non-operating pension and other post-retirement employee benefit income for the three months ended March 31, 2017.
|
|
Three Months Ended March 31, 2017 |
|
|||||||||
|
|
|
|
|
|
ASU 2017-07 |
|
|
|
|
|
|
|
|
As Reported |
|
|
Adjustments |
|
|
As Reclassified |
|
|||
Net sales |
|
$ |
1,437 |
|
|
$ |
— |
|
|
$ |
1,437 |
|
Cost of goods sold |
|
|
1,079 |
|
|
|
2 |
|
|
|
1,081 |
|
Gross profit |
|
|
358 |
|
|
|
(2 |
) |
|
|
356 |
|
Selling, general, and administrative expense |
|
|
144 |
|
|
|
6 |
|
|
|
150 |
|
Research and development expense |
|
|
19 |
|
|
|
— |
|
|
|
19 |
|
Restructuring, asset-related, and other charges, net |
|
|
12 |
|
|
|
— |
|
|
|
12 |
|
Total expenses |
|
|
175 |
|
|
|
6 |
|
|
|
181 |
|
Equity in earnings of affiliates |
|
|
7 |
|
|
|
— |
|
|
|
7 |
|
Interest expense, net |
|
|
(51 |
) |
|
|
— |
|
|
|
(51 |
) |
Other income, net |
|
|
34 |
|
|
|
8 |
|
|
|
42 |
|
Income before income taxes |
|
|
173 |
|
|
|
— |
|
|
|
173 |
|
Provision for income taxes |